Israeli Researchers Find Cannabis Compounds May Lead to First Fatty Liver Disease Drug

Hebrew University researchers have discovered that two non-psychoactive cannabis compounds, CBD and CBG, show significant promise in treating metabolic dysfunction-associated steatotic liver disease (MASLD), commonly known as fatty liver disease. The peer-reviewed study, published in The British Journal of Pharmacology and led by Prof. Yossi Tam, found that the compounds improved liver function through metabolic remodeling in mice. MASLD affects approximately one in three adults worldwide and currently has no approved pharmaceutical treatment. The Hebrew University lab has patented the CBD-CBG combination and aims to advance toward human clinical trials.